Methods of T Cell Depletion Trial (MoTD)

  • STATUS
    Recruiting
  • End date
    Jun 24, 2025
  • participants needed
    400
  • sponsor
    University of Birmingham
Updated on 24 May 2021

Summary

A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.

Description

This is a prospective, phase II, adaptive, multicentre, randomised clinical trial in patients undergoing reduced intensity conditioned (RIC) unrelated donor allogeneic stem cell transplantation (allo-SCT). The trial will compare the novel graft-versus-host disease (GvHD) prophylaxis regimens of post-transplant cyclophosphamide (PTCy) + Calcineurin inhibitor (CNI) (PTCy-CNI) or PTCy + Sirolimus to a current standard-of-care involving the use of T-cell depletion with Thymoglobulin. Patients will be minimised at randomisation by their randomising centre, disease risk score (low/intermediate or high/very high) and human leukocyte antigen (HLA) match (10/10 or 9/10). Patients eligible for entry into the trial will be randomised on a 1:1:1 ratio to receive either one of the experimental treatment arms or the control arm.

The primary objective is to compare GvHD-free, relapse-free Survival (GRFS) in patients treated with the GvHD prophylaxis regimens PTCy-CNI, PTCy-Sirolimus or T-cell depletion with Thymoglobulin.

The secondary objectives are to evaluate the cumulative incidence of acute GvHD (aGvHD), the cumulative incidence of moderate and severe chronic GvHD (cGvHD), the cumulative incidence of non-relapse mortality (NRM), overall survival (OS), progression-free survival (PFS), immune suppression-free survival, the cumulative incidence of engraftment, the incidence of full donor chimerism, the cumulative incidence of infection requiring inpatient admission, the number of inpatient days, the timing and dose of donor lymphocyte infusion (DLI), the cumulative incidence of Epstein-Barr virus (EBV) related-post transplant lymphoproliferative disease (PTLD), the number of doses rituximab administered for EBV reactivation, quality of life (QoL), the cumulative incidence of haemorrhagic cystitis, the cumulative incidence of cytomegalovirus (CMV) viraemia and CMV end-organ disease and safety and tolerability.

The scientific research will address the questions about how plasma biomarkers for GvHD predict GvHD and non-relapse mortality following T-cell depleted methods of transplantation and how the different methods of T-cell depletion impact on immune function and re-constitution.

Outcome Measures

Primary Outcome Measure:

GvHD-free, relapse-free survival at 1 year

Secondary Outcome Measures:

  • Cumulative incidence of acute grade II-IV and III-IV GvHD at 1 year
  • Cumulative incidence of moderate and severe chronic GvHD at 1 year
  • Cumulative incidence of NRM at 1 year
  • Overall survival at 1 year
  • Progression-free survival at 1 year
  • Immune suppression-free survival at 1 year
  • Cumulative incidence of engraftment at 1 year
  • The incidence of full donor chimerism at 100 days
  • The cumulative incidence of infection requiring inpatient admission at 1 year
  • The number of inpatient days during first 12 months
  • The timing and dose of DLI for mixed chimerism, persistent disease or relapse
  • Cumulative incidence of EBV-related PTLD
  • The number of doses of rituximab administered for EBV reactivation during first 12 months
  • QoL measured by FACT-BMT questionnaire at baseline, 6 months and 12 months
  • Cumulative incidence of patients with haemorrhagic cystitis at 1 year
  • Cumulative incidence of CMV viremia and CMV end-organ disease at 1 year
  • Safety defined as the incidence of grade 3 toxicities reported as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0
  • Tolerability defined to be the number of patients able to complete therapy as scheduled

Exploratory Outcome Measures:

The scientific research will address the following questions:

  1. Do plasma biomarkers for GvHD predict GvHD and non-relapse mortality following T-cell depleted methods of transplantation?
  2. Do PTCy methods increase T cell receptor repertoire diversity (as measured by TCR DNA sequencing) compared to ATG-based T cell depletion?
  3. How do the different methods of T-cell depletion impact upon donor Treg reconstitution?
  4. How do the different methods of T-cell depletion impact upon thymic function as evaluated by measurement of recent thymic emigrants?
  5. Are PTCy methods of TCD associated with better preservation of virus-specific immunity (as measured by tetramer or ex vivo functional immune responses)?

Patient Population

Adults considered suitable for an allo-SCT with the following haematological malignancies will be recruited to this trial:

  • Acute Myeloid Leukaemia (AML)
  • Acute lymphoblastic leukaemia (ALL)
  • Chronic myelomonocytic leukemia (CMML)
  • Myelodysplastic syndromes (MDS)
  • Non-Hodgkin lymphoma (NHL)
  • Hodgkin lymphoma (HL)
  • Multiple myeloma (MM)
  • Chronic lymphocytic leukaemia (CLL)
  • Chronic myeloid leukaemia (CML)
  • Myelofibrosis

Sample Size:

Up to 400 patients will be randomised to the MoTD trial across IMPACT centres.

Trial Duration:

Patients will be recruited over 48 months. Patients will be followed up for a minimum of 1 year.

MoTD Trials Office Contact Details:

MoTD trials office, Centre for Clinical Haematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH Tel: 0121 371 7858 Email: MoTD@trials.bham.ac.uk

Details
Condition graft-versus-host-disease, Graft-Versus-Host Disease (GVHD), Graft-Versus-Host Disease, graft versus host disease
Treatment cyclophosphamide, cyclosporine, mycophenolate mofetil, Sirolimus, Thymoglobulin
Clinical Study IdentifierNCT04888741
SponsorUniversity of Birmingham
Last Modified on24 May 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Availability of suitably matched unrelated donor (9/10 or 10/10)
Planned to receive one of the following RIC protocols
Fludarabine-Melphalan (Fludarabine 120-180mg/m2 IV; melphalan 150mg/m2 IV)
BEAM or LEAM (carmustine 300mg/m2 IV or lomustine 200mg/m2 IV with: etoposide 800 mg/m2 IV; cytarabine 1600mg/m2 IV; melphalan 140mg/m2 IV)
Fludarabine-Busulphan (Fludarabine 120-180mg/m2 IV; Busulphan 8mg/kg PO or 6.4mg/kg IV)
Planned use of PBSCs for transplantation
Planned allo-SCT for one of the following haematological malignancies
AML in CR (patients enrolled onto the COSI trial are not eligible for this study)
ALL in CR (patients enrolled onto the ALL-RIC trial are not eligible for this study)
CMML <10% blasts
MDS <10% blasts (patients enrolled onto the COSI trial are not eligible for this study)
NHL in CR/PR
HL in CR/PR
MM in CR/PR
CLL in CR/PR
CML in 1st or 2nd chronic phase
Myelofibrosis
Age 16-70 years
Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must agree to use appropriate, highly effective, contraception from the point of commencing therapy until 12 months after transplant

Exclusion Criteria

Use of any method of graft manipulation (excluding storage of future DLI)
Use of alemtuzumab or any method of T cell depletion except those that are protocol-defined
Known hypersensitivity to study drugs or history of hypersensitivity to rabbits
Pregnant or lactating women
Adults of reproductive potential not willing to use appropriate, highly effective, contraception during the specified period
Life expectancy <8 weeks
Active HBV or HCV infection
Organ dysfunction defined as
LVEF <45%
GFR <50ml/min
Bilirubin >50mol/l
AST/ALT>3 x ULN
Participation in COSI or ALL-RIC trials
Contraindication to treatment with the study drugs (Thymoglobulin, cyclophosphamide, sirolimus, ciclosporin and mycophenolate mofetil) as detailed in each study drug SPC
Patient has any other systemic dysfunction (e.g., gastrointestinal, renal, respiratory, cardiovascular) or significant disorder which, in the opinion of the investigator would jeopardise the safety of the patient by taking part in the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note